Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-7011a in Systemic Lupus Erythematosus
NCT05638802Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of DS-7011a in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), sponsored by Daiichi Sankyo Co., Ltd.. Started Jun 2023; status: completed.
02
Drugs
DS-7011a
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT05638802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638802.